These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24076063)

  • 1. Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study.
    Thangavelu A; Hewitt MJ; Quinton ND; Duffy SR
    Gynecol Oncol; 2013 Dec; 131(3):613-8. PubMed ID: 24076063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
    Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
    Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
    Mattar A; Logullo AF; Facina G; Nonogaki S; Soares FA; Gebrim LH
    J Cancer Res Clin Oncol; 2011 May; 137(5):897-905. PubMed ID: 20886231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
    Bershteĭn LM; Danilova MA; Kovalevskiĭ AIu; Gershfel'd ED; Poroshina TE; Tsyrlina TE; Meshkova IE; Turkevich EA; Maksimov SIa
    Vopr Onkol; 2009; 55(3):314-8. PubMed ID: 19670731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
    Shoji K; Oda K; Nakagawa S; Kawana K; Yasugi T; Ikeda Y; Takazawa Y; Kozuma S; Taketani Y
    Med Oncol; 2011 Sep; 28(3):771-4. PubMed ID: 20354812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].
    Lisianskaia AS; Manikhas GM; Fadeeva EP; Fedosenko KV; Tapil'skaia NI
    Vopr Onkol; 2010; 56(1):91-3. PubMed ID: 20361625
    [No Abstract]   [Full Text] [Related]  

  • 7. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
    Barker LC; Brand IR; Crawford SM
    Curr Med Res Opin; 2009 May; 25(5):1105-9. PubMed ID: 19301987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR; Stuart M; Sahmoud T; Dixon JM
    Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
    Bellone S; Shah HR; McKenney JK; Stone PJ; Santin AD
    Am J Obstet Gynecol; 2008 Sep; 199(3):e7-e10. PubMed ID: 18550023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
    Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
    J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
    Jonat W; Howell A; Blomqvist C; Eiermann W; Winblad G; Tyrrell C; Mauriac L; Roche H; Lundgren S; Hellmund R; Azab M
    Eur J Cancer; 1996 Mar; 32A(3):404-12. PubMed ID: 8814682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
    Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
    Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
    Bogliolo S; Gardella B; Dominoni M; Musacchi V; Cassani C; Zanellini F; De Silvestri A; Gaggero CR; Babilonti L; Spinillo A
    Arch Gynecol Obstet; 2016 Apr; 293(4):701-8. PubMed ID: 26671487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
    Dixon JM; Jackson J; Renshaw L; Miller WR
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
    Anderson TJ; Dixon JM; Stuart M; Sahmoud T; Miller WR
    Br J Cancer; 2002 Jul; 87(3):334-8. PubMed ID: 12177804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
    Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.